References
- Epelbaum R., Faraggi D., Ben-Arie Y., et al. Survival of diffuse large cell lymphoma. Cancer 1990; 60: 1124–1129
- Meyer R.M., Hryniuk W.H., Goodyear D.E. The role of dose intensity in determining outcome in intermediate grade non-Hodgkin's lymphoma. J. Clin. Oncol. 1991; 9: 339–342
- Armitage J.O. The treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1023–1030
- Gabrilove J.L., Jakubowski A., Scher H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med. 1988; 318: 1414–1422
- Morstyn G., Campbell C., Souza L., et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 2: 667–672
- Morstyn G., Campbell C., Lischke G., et al. Treatment of chemotherapy induced neutropenia by subcutaneous administration of granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989; 7: 1554–1562
- Bronchud M.H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T.M. The of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast cancer. Br. J. Cancer 1989; 60: 121–125
- Hougaard D.J., Nissen N.I. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease. A phase I/II study. J. Clin. Oncol. 1992; 10: 390–397
- Yoshida T., Najamura S., Ohtake S., et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma. Cancer 1990; 66: 1904–1909
- Biesma B., Valenga E., Willemze P. H. B., De Vries E. G. E. Effect of hematopoietic growth factors on chemotherapy-induced myelosuppression. Crit. Rev. Oncol. Hematol. 1992; 13: 107–134
- The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Cancer 1982; 49: 2112–2135
- Avites A., Dfaz-Maqueo J.C., Rodriguez L., et al. Group-risk classification of non-Hodgkin's lymphoma. Arch. Invest. Med. 1990; 21: 11–16
- Avites A., Zepeda G., Dfaz-Maqueo J.C., et al. Beta 2 microglobulin level as indicator of prognosis in diffuse large cell lymphoma. Leukemia and Lymphoma 1992; 7: 135–138
- World Health Organization. “WHO Handbook for reporting results of cancer treatment”. Geneve, Switzerland 1979, WHO Offset Publication No. 48
- Hryniuk W.H. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology, V.T. DeVita, Jr., S. Hellman, S.A. Rosenberg. J. B. Lippincott, Philadelphia 1988; 121–147
- De Vita V.T., Jr, Hubbards S.M., Longo D.L. The chemotherapy of lymphomas: Looking back moving forward. Cancer Res. 1987; 47: 5810–5824
- Klimo P., Connors J.M. Updated clinical experience with MACOP-B. Semin. Oncol. 1987; 24: 26–34
- Weick J.K., Dahlberg S., Fisher R.I., et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B. A Southwest Oncology Group Study. J. Clin. Oncol. 1991; 9: 748–753
- Gaynor R.I., Fisher E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
- Dodwell D.J., de Campos E.J., Radford J.A. Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. Much is better?. Drugs 1992; 44: 1–8